Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.

Zhu H, Yang B, Lu L, Li Y, Sui R, Liu K, Tan S, Wang L, Qiu J, Zhong J, Wei T, Bei Y and 15 more

Show all authors

Huang J, Zhang S, Ji Y, Wu W, Li Y, Huang Y, Chen Y, Huang X, Zeng G, Zhang Y, Huang L, Li H, Wang X, Wang Y, Xu A

JAMA internal medicine1 Jan 2026Cited by 10 (Europe PMC)

PMID41182740PMCIDPMC12584062DOI10.1001/jamainternmed.2025.5684PepBankPUB-41182740

Download PDF PubMedAsk about this study

Jump to 4 results

Summary

ImportanceGlucagon-like peptide-1 receptor agonists can reduce the risk of cardiovascular events in patients with high-risk type 2 diabetes (T2D). However, dedicated randomized clinical trials that evaluate their efficacy in acute ischemic stroke are lacking.ObjectiveTo investigate the safety and efficacy of liraglutide in patients with T2D and minor acute ischemic stroke (AIS) or high-risk transient ischemic attack (TIA).Design, setting, and participantsThe LAMP trial was designed as a multicenter, controlled, prospective, randomized, open-label, blinded end point trial and conducted at 27 hospitals in China from June 25, 2019, through December 27, 2023. The final follow-up was on March 24, 2024. Data were analyzed on May 1, 2024. The study included patients with T2D who had minor AIS (National Institutes of Health Stroke Scale score ≤3) or high-risk TIA (ABCD2 score [age, blood pressure elevation on first assessment after TIA, unilateral weakness, speech disturbance, duration of symptoms and diabetes] ≥4).InterventionsEligible patients were randomized within 24 hours of symptom onset to the liraglutide group and the control group. Both groups received standard treatment according to the guidelines. The liraglutide group received liraglutide once daily for 90 days (0.6 mg for the first week, which was increased to 1.2 mg in the second week and followed by 1.8 mg until day 90) in addition to standard therapy.Main outcomes and measuresThe primary outcome was stroke recurrence (ischemic or hemorrhagic) after 90 days, and the safety outcome was symptomatic intracranial hemorrhage and all-cause mortality at 90 days.ResultsIn all, 636 patients (median [IQR] age, 63.5 [57.8-70.0] years; 231 female individuals [36.3%]) were randomized. Within 90 days, 25 patients (7.9%) in the liraglutide group and 44 (13.8%) in the control group experienced stroke recurrence (hazard ratio, 0.56; 95% CI, 0.34-0.91; P = .02). A significantly higher proportion of patients (modified Rankin Scale score, ≤1) in the liraglutide group (274 [87.3%]) than in the control group (246 [77.8%]) achieved excellent functional outcomes (odds ratio, 1.95; 95% CI, 1.28-3.00; P = .002). The rates of symptomatic intracranial hemorrhage and all-cause mortality were low and similar between the groups.Conclusions and relevanceThe trial results suggest that among Chinese patients with T2D and minor AIS or high-risk TIA, liraglutide treatment might reduce stroke recurrence and improve 90-day outcomes. However, given the underpowered nature of the study, these findings should be interpreted with caution.Trial registrationClinicalTrials.gov Identifier: NCT03948347.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In 636 people with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack receiving standard therapy, liraglutide reduced recurrent stroke risk (HR 0.56, 95% CI 0.34-0.91; P=.02).
In plain wordsIn diabetes with minor stroke or high-risk TIA, liraglutide plus standard therapy reduced recurrent strokes versus standard therapy alone; the trial was underpowered.
Peptide
Liraglutide
Outcome
DecreaseStroke recurrence within 90 days
Study
n = 636
Comparator
Control group
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
0.6 mg for the first week, increased to 1.2 mg in the second week and 1.8 mg until day 90 · 90 daysAs given in this study (human).
Measurements
Stroke recurrence
7.9%
liraglutide group
Stroke recurrence
13.8%
control group
Source sentences
Summary
Within 90 days, 25 patients (7.9%) in the liraglutide group and 44 (13.8%) in the control group experienced stroke recurrence (hazard ratio, 0.56; 95% CI, 0.34-0.91; P = .02).
4 context sentences(design, population, supporting numbers)
Summary · context
The study included patients with T2D who had minor AIS (National Institutes of Health Stroke Scale score ≤3) or high-risk TIA (ABCD2 score [age, blood pressure elevation on first assessment after TIA, unilateral weakness, speech disturbance, duration of symptoms and diabetes] ≥4).
Summary · context
Both groups received standard treatment according to the guidelines.
Summary · context
The liraglutide group received liraglutide once daily for 90 days (0.6 mg for the first week, which was increased to 1.2 mg in the second week and followed by 1.8 mg until day 90) in addition to standard therapy.
Summary · context
However, given the underpowered nature of the study, these findings should be interpreted with caution.
Show in the study text Report a problemFND-4118274001
02HumanRandomized controlled trialSafety outcome
In 636 people with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack receiving standard therapy, symptomatic intracranial hemorrhage rates were low and similar with liraglutide and control.
In plain wordsAfter minor stroke or high-risk TIA with diabetes, symptomatic brain bleeding was low and similar with liraglutide plus standard therapy and standard therapy alone.
Peptide
Liraglutide
Outcome
Not applicableSymptomatic intracranial hemorrhage
Study
n = 636
Comparator
Control group
Outcome group
Adverse events · Nervous system and cognition
Studied dose
0.6 mg for the first week, increased to 1.2 mg in the second week and 1.8 mg until day 90 · 90 daysAs given in this study (human).
Source sentences
Summary
The rates of symptomatic intracranial hemorrhage and all-cause mortality were low and similar between the groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study included patients with T2D who had minor AIS (National Institutes of Health Stroke Scale score ≤3) or high-risk TIA (ABCD2 score [age, blood pressure elevation on first assessment after TIA, unilateral weakness, speech disturbance, duration of symptoms and diabetes] ≥4).
Summary · context
Both groups received standard treatment according to the guidelines.
Summary · context
The liraglutide group received liraglutide once daily for 90 days (0.6 mg for the first week, which was increased to 1.2 mg in the second week and followed by 1.8 mg until day 90) in addition to standard therapy.
Show in the study text Report a problemFND-4118274003
03HumanRandomized controlled trialSafety outcome
In 636 people with type 2 diabetes and minor ischemic stroke or high-risk transient ischemic attack receiving standard therapy, mortality was low and similar with liraglutide and control.
In plain wordsIn diabetes with minor stroke or high-risk TIA, death rates were low and similar with liraglutide plus standard therapy and standard therapy alone.
Peptide
Liraglutide
Outcome
Not applicableAll-cause mortality at 90 days
Study
n = 636
Comparator
Control group
Outcome group
Mortality · Whole body
Studied dose
0.6 mg for the first week, increased to 1.2 mg in the second week and 1.8 mg until day 90 · 90 daysAs given in this study (human).
Source sentences
Summary
The rates of symptomatic intracranial hemorrhage and all-cause mortality were low and similar between the groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study included patients with T2D who had minor AIS (National Institutes of Health Stroke Scale score ≤3) or high-risk TIA (ABCD2 score [age, blood pressure elevation on first assessment after TIA, unilateral weakness, speech disturbance, duration of symptoms and diabetes] ≥4).
Summary · context
Both groups received standard treatment according to the guidelines.
Summary · context
The liraglutide group received liraglutide once daily for 90 days (0.6 mg for the first week, which was increased to 1.2 mg in the second week and followed by 1.8 mg until day 90) in addition to standard therapy.
Show in the study text Report a problemFND-4118274004
04HumanRandomized controlled trialEfficacy outcome
In Chinese patients with type 2 diabetes and minor ischemic stroke or high-risk TIA, liraglutide plus standard therapy improved excellent functional outcome versus standard therapy alone (OR 1.95; 95% CI 1.28-3.00; P=.002).
In plain wordsIn diabetes with minor stroke or high-risk TIA, liraglutide plus standard therapy improved functional outcomes versus standard therapy alone; the trial was underpowered.
Peptide
Liraglutide
Outcome
IncreaseExcellent functional outcome at 90 days
Study
n: not reported in source
Comparator
Control group
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
0.6 mg for the first week, increased to 1.2 mg in the second week and 1.8 mg until day 90 · 90 daysAs given in this study (human).
Measurements
Excellent functional outcome
87.3%
liraglutide group
Excellent functional outcome
77.8%
control group
Source sentences
Summary
A significantly higher proportion of patients (modified Rankin Scale score, ≤1) in the liraglutide group (274 [87.3%]) than in the control group (246 [77.8%]) achieved excellent functional outcomes (odds ratio, 1.95; 95% CI, 1.28-3.00; P = .002).
4 context sentences(design, population, supporting numbers)
Summary · context
The study included patients with T2D who had minor AIS (National Institutes of Health Stroke Scale score ≤3) or high-risk TIA (ABCD2 score [age, blood pressure elevation on first assessment after TIA, unilateral weakness, speech disturbance, duration of symptoms and diabetes] ≥4).
Summary · context
Both groups received standard treatment according to the guidelines.
Summary · context
The liraglutide group received liraglutide once daily for 90 days (0.6 mg for the first week, which was increased to 1.2 mg in the second week and followed by 1.8 mg until day 90) in addition to standard therapy.
Summary · context
However, given the underpowered nature of the study, these findings should be interpreted with caution.
Show in the study text Report a problemFND-4118274002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT03948347

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

First Affiliated Hospital of Jinan Universityn = 1,70825 Jun 2019 to est. Jun 2024

Ischemic Stroke · Transient Ischemic Attack · Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 6 Feb 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.